<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129490">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01416363</url>
  </required_header>
  <id_info>
    <org_study_id>115517</org_study_id>
    <nct_id>NCT01416363</nct_id>
  </id_info>
  <brief_title>Healthy Volunteer Study Using 3 Different Formulations of Firategrast</brief_title>
  <official_title>A Single/Repeat Dose Study With Three Oral Formulations of Firategrast (Immediate Release Tablet, Modified Release Tablet, and Naso-gastric Infusion) in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate how 3 types of drug formulations are absorbed by the body. This
      study is termed 'open-label', which means volunteers will be aware of which treatment they
      are receiving. The study is split into 2 parts. Part 1, involves volunteers receiving 2 new
      formulations, as a single dose. There is no placebo (dummy-drug; no active ingredient) in
      this study. Volunteers will also receive a single dose of a formulation used in previous
      trials (reference formulation), so a proper comparison with the new formulations can be
      made. The new fomulations will be administered with food and the reference formulation will
      be given without food. In Part 2, volunteers will receive only one of the 3 formulations as
      a repeat dose for 7 days. Each of these doses will be given with food.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study will be conducted in two parts in healthy male volunteers. Part 1 will
      investigate the pharmacokinetics and tolerability of single doses of firategrast
      administered as the existing immediate release tablet formulation, as a modified release
      tablet (3hr) formulation and as a simulated gastro-retentive formulation to be administered
      via a naso-gastric tube. Subjects will receive each formulation in a randomised 3-way single
      dose crossover fashion.

      Part 2, based on the review of safety, tolerability and pharmacokinetic data from the first
      two study treatment periods of Part 1, will investigate the pharmacokinetics and
      tolerability of multiple doses of firategrast administered as the existing immediate release
      tablet formulation, as a modified release tablet (3hr) formulation and as simulated
      gastro-retentive formulation to be administered via naso-gastric tube for a period of 7
      days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic measures for single and repeat dose</measure>
    <time_frame>Part 1: approx. 4 weeks, Part 2: approx 8 days</time_frame>
    <description>Cmax of firategrast</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK measures for single and repeat dose</measure>
    <time_frame>Part 1 approx 4 weeks, Part 2 approx 8 days</time_frame>
    <description>AUC(0-t) of firategrast</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic measurements for single and repeat dose</measure>
    <time_frame>Part 1: approx 4 weeks, Part 2: approx 8 days</time_frame>
    <description>AUC(0-24) of firategrast</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety &amp; Tolerability in single and repeat doses</measure>
    <time_frame>Part 1: approx. 4 weeks, Part 2: approx 8 days</time_frame>
    <description>Adverse events, changes iin blood pressure, heart rate, ECGs, Haematology, clinical chemistry and urinalysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD34 positive cell count</measure>
    <time_frame>Part 1 only approx 4 weeks</time_frame>
    <description>as data permit - exploratory measure</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <arm_group>
    <arm_group_label>Firategrast immediate release tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Firategrast modified release tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Firategrast gastro-retentive solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A</intervention_name>
    <description>Single dose Firategrast immediate release formulation</description>
    <arm_group_label>Firategrast immediate release tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B</intervention_name>
    <description>Single dose Firategrast modified release formulation</description>
    <arm_group_label>Firategrast modified release tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C</intervention_name>
    <description>Single dose Firategrast simulated gastro-retentive formulation</description>
    <arm_group_label>Firategrast gastro-retentive solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D</intervention_name>
    <description>Repeat dose Firategrast immediate release formulation</description>
    <arm_group_label>Firategrast immediate release tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E</intervention_name>
    <description>Repeat dose Firategrast modified release formulation</description>
    <arm_group_label>Firategrast modified release tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F</intervention_name>
    <description>Repeat dose Firategrast simulated gastro-retentive formulation</description>
    <arm_group_label>Firategrast gastro-retentive solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male aged 18 to 65 yrs inclusive

          -  Healthy, as determined by study physician

          -  Capable of giving iformed consent

        Exclusion Criteria:

          -  Positive drugs of abuse result

          -  Positive for HIV or Hepatitis B and/or C viruses

          -  History of alcohol consumption in excess of average recommended weekly intake (more
             than 12 units for males)

          -  Participation in a clinical trial within 30 days of scheduled first dose
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <lastchanged_date>March 8, 2012</lastchanged_date>
  <firstreceived_date>June 23, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>firategrast</keyword>
  <keyword>pharmacokinetics, modified release, firategrast,</keyword>
  <keyword>simulated gastro-retentive</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>healthy volunteers, simulated gastro-retentive</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>modified release</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
